Schizophrenia Clinical Trial
Official title:
The Effect of Cigarette Holders, Plastic Menthol Cigarettes, and Cognitive Behavioral Therapy for Smoking Reduction Among Schizophrenia Inpatients: A Comparative Study
This study aims:
1. to assess the effect of smoking reduction programs (behavior therapy alone or behavior
therapy with cigarette holders; "Flowers Menthol" plastic cigarettes with menthol) on
cigarette smoking habits in an antipsychotic treated schizophrenia population.
Smoking is a leading preventable cause of death in the western world. The highest incidence
of smoking is among psychiatric inpatients. The issue of smoking among psychiatric patients
needs to be addressed, since this population already suffers from physical comorbidity and
reduced life expectancy (Brown et al., 2000), which increase with smoking, considering the
additional risk factors for cardiovascular diseases: obesity, high cholesterol, diabetes. In
addition the increased risk factors associated with second generation antipsychotic
treatment need to be considered. Significant financial expenditures for the purchase of
cigarettes, from an already extremely limited budget (Steinberg et al., 2004) should be
taken into account. Psychiatric patients who smoke spend up to 30% of their welfare payments
on cigarettes.
A survey performed in our mental health center revealed that over 30% of the patients who
smoke are interested in specific treatment to reduce/stop smoking (Melamed et al.,
unpublished). Our survey found that The expressed desire of the patients to quit smoking and
the known dangers of smoking, especially in this population, reflect the importance of
integrating smoking reduction/cessation programs into the treatment regimens of psychiatric
inpatients.
Treatment options to promote smoking cessation include hypnosis (Spiegel et la., 1993;
Weizman et al., 2004), behavior therapy (Addington et al., 1998), group therapy (Addington,
1998), nicotine replacement therapies (NRT) (Fant et al., 2000), and pharmacotherapy such as
bupropion (George et al., 2002).
Since it is recommended that many smoking cessation treatment options such as NRT (nicotine
transdermal patches or nicotine polacrilex gum, nasal spray, cigarette filters and nicotine
inhalers) should not be used together with actual nicotine intake we decided to gradually
introduce the issue of smoking reduction/cessation to the inpatient population, by initially
introducing a program for smoking reduction.
Smoking reduction options include:
1. Cigarette holders
2. "Flowers Menthol"
3. Behavior therapy, including various relaxation techniques
Methods Study population: 60 subjects will be drawn from the inpatient population of
Lev-Hasharon Mental Health Center, and divided into 4 groups of 15 participants each.
Inclusion criteria
1. Age 18-65 male or female.
2. DSM -IV criteria for chronic schizophrenia or schizoaffective disorder.
3. Ability and willingness to sign informed consent for participation in the study.
4. Patients' expressed interest in participating in a smoking-reduction program
5. Smoking a minimum of 20 cigarettes daily, for 6 months prior to the study period, as
per patient report.
6. Patients treated with antipsychotic agents. Exclusion criteria
1- Significant physical illness. 2- Evidence of organic brain damage , mental retardation ,
alcohol or drug abuse.
3- Contraindication to amantadine treatment. 4- Pregnant or nursing female patients.
Duration of study will be 6 weeks. Patients will be assigned to one of 4 the intervention
groups. Group assignment will be according to the department where the patient is
hospitalized.
Group 1 - Behavior therapy only Group 2 - Behavior therapy with cigarette holders Group 3 -
Behavior therapy with "Flowers Menthol" There will be no restrictions regarding the type of
antipsychotic medication (typical or atypical) that participants are currently treated with.
Proposed study duration is 6 weeks. All patients will participate in 5 weekly behavioral
group therapy sessions for smoking reduction. Each department will have a staff member
devoted to smoking reduction "smoking supervisors" , who will accompany the patients
throughout the week, advising, counseling, and supporting during crises.
Group 1 will have behavioral group therapy for smoking reduction, with not additional
intervention.
Group 2 will be administered plastic cigarette holders. The nursing staff will distribute
the holders one at a time. Used holders will be returned to the "smoking supervisor" when
the sieve is blocked (usually after five cigarettes).
Group 3 will be administered Flowers Menthol (smokeless inhalers), one per day, by the
"smoking supervisor". Used devices will be returned to him/her.
After receiving a detailed explanation of study procedures patients will sign informed
consent. Throughout the study period, cigarettes will be distributed freely. Participants
will fill out tables recording the number of cigarettes smoked, with the help of their
"smoking supervisors".
Instruments
Patients will be assessed at baseline, and end of week 6 with the following instruments:
Clinical Rating Scales The patients' mental condition will be assessed with the Positive and
Negative Syndrome Scale (PANSS) (Kay et al, 1987), Clinical Global Impression (CGI) scale
for psychosis (Guy,1976), Hamilton Rating Scale for Depression (HAM-D) (Hamilton,1960),
Simpson Angus Scale for extrapyramidal side effects (SAS) (Simpson and Angus 1970).
Assessment of smoking dependence The Fagerstrom Tolerance Questionnaire for Nicotine
Dependence (FTND Fagerstrom KO 1978) is useful and simple to administer for the evaluation
of nicotine dependence.
Weekly table for self-report of the number of cigarettes smoked will be filled out by
participants with the help of the "smoking supervisors".
Subjective Quality of Life Quality of life enjoyment and satisfaction questionnaire
-abbreviated version (Q-LES-Q-18) (Ritsner et al., 2005).
Statistical analysis Appropriate statistical analysis will be performed including ANOVA with
repeated measures.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
| Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
| Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
| Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
| Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
| Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
| Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
| Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
| Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
| Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
| Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
| Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
| Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
| Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
| Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
| Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
| Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |